Inmune Bio Files 8-K: Material Agreement & Exhibits
Ticker: INMB · Form: 8-K · Filed: Dec 23, 2025 · CIK: 1711754
| Field | Detail |
|---|---|
| Company | Inmune Bio, Inc. (INMB) |
| Form Type | 8-K |
| Filed Date | Dec 23, 2025 |
| Risk Level | medium |
| Pages | 2 |
| Reading Time | 2 min |
| Key Dollar Amounts | $0.001, $1, $0.05, $67,416 |
| Sentiment | neutral |
Sentiment: neutral
Topics: material-agreement, exhibits
Related Tickers: INMB
TL;DR
INMB filed an 8-K on 12/22/25 for a material agreement and exhibits.
AI Summary
On December 22, 2025, Inmune Bio, Inc. filed an 8-K report. The filing indicates an entry into a material definitive agreement and includes financial statements and exhibits. The company, incorporated in Nevada, is involved in biological products.
Why It Matters
This filing signals a significant development for Inmune Bio, Inc., potentially involving new partnerships or financial arrangements that could impact its future operations and stock performance.
Risk Assessment
Risk Level: medium — 8-K filings often disclose material events that can significantly impact a company's stock price, requiring careful investor attention.
Key Players & Entities
- Inmune Bio, Inc. (company) — Registrant
- December 22, 2025 (date) — Date of earliest event reported
- Nevada (jurisdiction) — State of incorporation
- 225 NE Mizner Blvd. , Suite 640 , Boca Raton , Florida 33432 (address) — Principal Executive Offices
- 561-710-0512 (phone_number) — Registrant's Telephone Number
FAQ
What is the nature of the material definitive agreement entered into by Inmune Bio, Inc.?
The filing does not specify the details of the material definitive agreement, only that one was entered into on or before December 22, 2025.
When was the earliest event reported in this 8-K filing?
The earliest event reported in this 8-K filing was on December 22, 2025.
Where is Inmune Bio, Inc. incorporated?
Inmune Bio, Inc. is incorporated in Nevada.
What is the principal executive office address for Inmune Bio, Inc.?
The principal executive office address is 225 NE Mizner Blvd., Suite 640, Boca Raton, Florida 33432.
What is the SIC code for Inmune Bio, Inc.?
The Standard Industrial Classification (SIC) code for Inmune Bio, Inc. is 2836, which corresponds to Biological Products (No Diagnostic Substances).
Filing Stats: 558 words · 2 min read · ~2 pages · Grade level 10.9 · Accepted 2025-12-23 16:00:32
Key Financial Figures
- $0.001 — ch registered Common Stock, par value $0.001 per shares INMB The NASDAQ Stock Ma
- $1 — April 2024 Warrants was (i) reduced to $1.95, which price is greater than Minimum
- $0.05 — Amendment, the holders paid the Company $0.05 per April 2024 Warrant, for aggregate p
- $67,416 — 2024 Warrant, for aggregate proceeds of $67,416. The foregoing summary of the Warrant
Filing Documents
- ea0270723-8k_inmune.htm (8-K) — 24KB
- ea027072301ex10-1_inmune.htm (EX-10.1) — 12KB
- 0001213900-25-125282.txt ( ) — 200KB
- inmb-20251222.xsd (EX-101.SCH) — 3KB
- inmb-20251222_lab.xml (EX-101.LAB) — 33KB
- inmb-20251222_pre.xml (EX-101.PRE) — 22KB
- ea0270723-8k_inmune_htm.xml (XML) — 3KB
01 Entry into a Material Definitive Agreement
Item 1.01 Entry into a Material Definitive Agreement. On December 22, 2025, INmune Bio Inc. (the "Company") entered into an amendment (the "Warrant Amendment") with certain holders of warrants previously issued by the Company in its April 2024 offerings on April 24, 2024 and April 29, 2024, respectively (the "April 2024 Warrants"). The exercise price of an aggregate of 1,348,315 outstanding April 2024 Warrants was (i) reduced to $1.95, which price is greater than Minimum Price (as defined in Nasdaq Listing Rule 5635(d)) as of December 17, 2025, and (ii) the term of such April 2024 Warrants was extended such that they will expire on June 30, 2026. As consideration for the Warrant Amendment, the holders paid the Company $0.05 per April 2024 Warrant, for aggregate proceeds of $67,416. The foregoing summary of the Warrant Amendment does not purport to be complete and is qualified in its entirety by reference to the form of the Warrant Amendment, a copy of which is filed as Exhibit 10.1 hereto and incorporated herein by reference. Item 9.01 Financial Statements and Exhibits. Exhibit No. Description 10.1 Form of Warrant Amendment 104 Cover Page Interactive Data File (embedded within the Inline XBRL document) 1
SIGNATURES
SIGNATURES Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized. INMUNE BIO INC. Date: December 23, 2025 By: /s/ David Moss David Moss Chief Executive Officer 2